Pharmacists in Preston, ID Accepting Medicare
3 Pharmacists found. Showing 1 - 3
 Dr. Seth William Haslam, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 39 North 1st East, Preston, ID 83263 Phone: 208-851-1561 Fax: 208-852-1268 |
Mr. Kimberly Gary Allen, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 44 N 1st E, Pharmacy, Preston, ID 83263 Phone: 208-852-4129 Fax: 208-852-3812 |
Aaron Henrie, RPHD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 39 N 1st E, Preston, ID 83263 Phone: 208-852-1563 |
News Archive
UTSA biologist recognized for showing leadership in advancing the discipline of reproductive biology
John McCarrey, professor of biology in the UTSA College of Sciences, has been selected to receive the Distinguished Service Award from the Society for the Study of Reproduction.
FDA's action impacts Elite pharma drugs
Elite Pharmaceuticals, Inc. advises that the US Food and Drug Administration announced that it intends to remove approximately 500 cough/cold and allergy related products from the U.S. market.
Shifts in zinc's location could be exploited for early diagnosis of prostate cancer
Zinc, an essential nutrient, is found in every tissue in the body. The vast majority of the metal ion is tightly bound to proteins, helping them to perform biological reactions. Tiny amounts of zinc, however, are only loosely bound, or "mobile," and thought to be critical for proper function in organs such as the brain, pancreas, and prostate gland. Yet the exact roles the ion plays in biological systems are unknown.
Cifra healthcare platform from Wound Management Technologies
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations, LLC has launched the Cifra(TM) healthcare platform to securely exchange and store information for ongoing evidence based case studies on its patented collagen CellerateRx® products in managing all types of wound care.
Neurologix completes Phase 2 clinical trial of Parkinson's study
Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company's gene transfer approach to the treatment of advanced Parkinson's disease.
› Verified 9 days ago